Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis

Company Overview

The market values Supernus Pharmaceuticals, Inc. (SUPN) at $2.40B. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 778.

The most recent close on file for SUPN is $41.21, dated October 21, 2026. That is −$0.02 (−0.05%) against the previous close. Over the past 52 weeks the price has ranged from $37.54 to $59.68. The latest close sits 9.78% above that 52-week low.

Financial Health

In fiscal 2025, Supernus Pharmaceuticals, Inc. reported revenue of $718.95M. Against the prior fiscal year total of $661.82M, that is a change of +8.63%. The same year closed with a net loss of $38.55M. The reported profit margin is −13.23%. That is 5.1 percentage points below the Drug Manufacturers - Specialty & Generic median of −8.14%. Trailing earnings per share are −1.92.

Across the 4 fiscal years on file, revenue moves from $667.24M in 2022 to $718.95M in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 9.63. Measured against sales, the shares trade at 2.89 times revenue. On price-to-sales that is 37.59% above the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

Beta against the wider market is reported at 0.55. Annualized volatility over the trailing 10 years is 43.6%. The trailing one-year total return is −18.67%. Across 10 years the annualized return works out at +7.06%.

Growth & Income

The record shows no dividend for SUPN.

The strongest complete calendar year on file is 2017 at +57.82%; the weakest is 2019 at −28.60%. Of the 9 complete calendar years on file, 6 finished higher. So far in 2026 the total return is −17.08%.